Gilead-Immunovaccine deal apparently ain't so

• According Immunovaccine, there is no collaboration agreement with Gilead Sciences (GILD -1.2%). The press release published earlier today was apparently fraudulent. The company says it uses Marketwired for its PRs, not GlobeNewswire and says that the bogus PR contained no accurate information.
• The post will be deleted from the SA site.